Relationship between HBV RNA level and pregnancy outcomes among hepatitis B carriers

HBV RNA Level & Pregnancy Outcomes in Hepatitis B Carriers

  • Manman Zhang
  • Xin Liao
  • Heng Wang
  • Huan Wu
  • Baofang Zhang Department of Infectious Diseases, Affiliated Hospital of Guizhou Medical University
DOI: https://doi.org/10.5937/jomb0-50420
Keywords: hepatitis B virus, serum marker, HBV RNA, pregnancy outcomes, intrahepatic cholestasis of pregnancy

Abstract


Background: This study aims at investigating the relationship HBV RNA level and pregnancy outcomes among hepatitis B carriers.

Methods: A total of 562 pregnant women who attended the Affiliated Hospital of Guizhou Medical University (Guizhou, China) from June 2020 to June 2023 were collected, 203 HBV carriers was included in this study. Then we recorded general data and pregnancy outcomes, the levels of HBV DNA, HBV RNA and HBeAg status in HBV carrier were detected. Pregnancy outcomes including intrahepatic cholestasis of pregnancy (ICP), gestational hypertension (GH), pre-eclampsia, gestational diabetes mellitus (GDM), preterm prelabour rupture of membranes (PPROM), mode of delivery , preterm birth, low birth weight (LBW) and macrosomia.

Results: 562 pregnancies were analyzed, 203(36.12%) were infected with hepatitis B virus. Compared with HBsAg negative, HBsAg positive pregnant women had a higher risk of ICP. No statistically significant differences were found in the rates of GDM, GH, pre-eclampsia, PPROM, preterm birth, LBW, macrosomia and mode of delivery among women with the two groups. The analysis of risk factors of ICP showed that maternal HBV RNA level (OR = 3.814, 95% CI: 2.036~7.142, P< 0.001) was an important risk factor for ICP in HBsAg positive pregnant women. The receiver operating characteristics (ROC) curve revealed that the areas under the HBV RNA was 0.8652(95% confidence interval 0.7636~0.9669, P< 0.001).

Conclusion: HBV RNA level pose significant negative impact to the pregnancy outcomes. It can be used as indicators to guide the prevention of ICP and improve maternal outcomes.

References

1. Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. B World Health Organ 2019; 97(3): 230-8.
2. Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology 2019; 69(4): 1816-27.
3. Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J Hepatol 2021; 75(3): 706-17.
4. Chinese Society of Hepatology, Chinese Medical Association。Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl). 2007 ;120(24):2159-73.
5. van Bommel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015; 61(1): 66-76.
6. Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antivir Res 2020; 182: 104925.
7. Wang Y, Liu Y, Liao H, Deng Z, Bian D, et al. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients. Int J Med Sci. 2022 ;19(5):858-866.
8. Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016; 65(4): 700-10.
9. Lin N, Ye A, Lin J, Liu C, Huang J, Fu Y, et al. Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes. J Clin Microbiol 2020; 58(2): e01275-19.
10. Wan Z, Zhou A, Zhu H, Lin X, Hu D, Peng S, et al. Maternal Hepatitis B Virus Infection and Pregnancy Outcomes: A Hospital-based Case-control Study in Wuhan, China. J Clin Gastroenterol 2018; 52(1): 73-8.
11. Cai Q, Liu H, Han W, Liu L, Xu Y, He Y, et al. Maternal HBsAg carriers and adverse pregnancy outcomes: A hospital-based prospective cohort analysis. J Viral Hepatitis 2019; 26(8): 1011-8.
12. Bajema KL, Stankiewicz KH, Tenforde MW, Hawes SE, Heffron R. Maternal Hepatitis B Infection and Pregnancy Outcomes in the United States: A Population-Based Cohort Study. Open Forum Infect Di 2018; 5(6): ofy134.
13. Keramat A, Younesian M, Gholami FM, Hasani M, Mirzaei S, Ebrahimi E, et al. Inactive Hepatitis B Carrier and Pregnancy Outcomes: A Systematic Review and Meta-analysis. Iran J Public Health 2017; 46(4): 468-74.
14. Palmer KR, Xiaohua L, Mol BW. Management of intrahepatic cholestasis in pregnancy. Lancet 2019; 393(10174): 853-4.
15. Abu-Hayyeh S, Ovadia C, Lieu T, Jensen DD, Chambers J, Dixon PH, et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 2016; 63(4): 1287-98.
16. Dixon PH, Wadsworth CA, Chambers J, Donnelly J, Cooley S, Buckley R, et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol 2014; 109(1): 76-84.
17. Anzivino C, Odoardi MR, Meschiari E, Baldelli E, Facchinetti F, Neri I, et al. ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Digest Liver Dis 2013; 45(3): 226-32.
18. Davit-Spraul A, Gonzales E, Jacquemin E. NR1H4 analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations. Clin Res Hepatol Gas 2012; 36(6): 569-73.
19. Jiang R, Wang T, Yao Y, Zhou F, Huang X. Hepatitis B infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. Medicine 2020; 99(31): e21416.
Published
2024/06/16
Issue
Ahead of print
Section
Original paper

Copyright (c) 2024 Manman Zhang, Xin Liao, Heng Wang, Huan Wu, Baofang Zhang

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.